Video

Peter Borchmann

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

17 December 2025
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

17 December 2025
Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myeloma: Phase II iMMagine-1 Resul

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

17 December 2025
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

17 December 2025
Exploring genomic insights in acute lymphoblastic leukaemia treatment

Exploring genomic insights in acute lymphoblastic leukaemia treatment

17 December 2025
Talquetamab plus Teclistamab in True Extramedullary Multiple Myeloma: Updated Results from the RedirecTT-1 Phase II Study

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

17 December 2025
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

16 December 2025
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

16 December 2025
Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

16 December 2025
Essential breast cancer medicines

Essential breast cancer medicines

12 December 2025
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

10 December 2025
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

10 December 2025
Back to Top